CorPath GRX is a second generation robotic-assisted system built on the foundation of the CorPath 200’s clinical success with over approximately 10,000 cases across more than 100 programs worldwide.
When using the CorPath System, studies have shown:*
The PRECISION GRX registry demonstrated 98.2% clinical success of all treated lesions, and 99.1% clinical success in CTO cases1,2
A single center study published in Circulation: Cardiovascular Interventions demonstrated a 20% reduction in radiation dose to the patient compared to manual PCI.2
A recent study demonstrated that accurate measurement of coronary anatomy, using CorPath, reduced the use of unnecessary additional stents by 8.3%.3
The PRECISE trial demonstrated a 95% reduction in radiation exposure to the primary operator.4
1. Mahmud E, et al. Safety and Efficacy of the Second Generation Robotic-Assisted System for Percutaneous Coronary Intervention: Final Results of the Multicenter PRECISION GRX Study. SCAI. 2021.
2. CTO lesions: typically first crossed manually before initiating treatment with the CorPath GRX system
3. Campbell PT, et al. The Impact of Precise Robotic Lesion Length Measurement on Stent Length Selection: Ramification for stent savings. Cardiovasc Revasc Med. 2015;piii:S1553-8389.
4. Weisz G, et al. Safety and Feasibility of Robotic Percutaneous Coronary Intervention: PRECISE Study. J American College of Cardiol, 2013, Vol 61, No. 15: 1596-1600.
* Includes studies conducted using CorPath 200
